The US is in the midst of another surge in COVID-19 infections heading into the summer. A GWU physician feels CDC are misserving the country by downplaying the surge and hiding the real data behind an “all green” map.

Although many studies have claimed that moderate alcohol consumption and drinks such as red wine can be healthy for the human heart, a new study presented at the European Society of Cardiology 2022 meeting takes a contrarian viewpoint and draws a link between alcohol consumption and heart failure in people with hypertension, diabetes, or obesity.

A new study published in Annals of Internal Medicine looks at the link between cardiovascular disease among adults with type 2 diabetes, which might be more prevalent than previously thought. This study compares cardiovascular outcomes in patients taking first line metformin vs. SGLT-2 inhibitors, based on claims data over a 7-year period. SGLT-2 inhibitor use was associated with lower rates of hospitalization for heart failure and all cause mortality. Rates for MI and stroke were similar for the two treatments.

Monkeypox is again spreading around the world, from Europe to North America. This is the first outbreak in US the since 2003 and the disease is now spreading fairly rapidly on a daily basis. Transmission between people mostly occurs through large respiratory droplets, normally meaning prolonged contact face to face. But the virus can also spread through bodily fluids. The latest cases have mainly been among men who have sex with men. Currently, the UK has the largest number of diagnosed cases, followed by Portugal, Canada, and Spain. Latest case counts by country can be seen here.

This one-credit activity features an expert panel providing their perspectives on the latest trends and emerging research regarding biomarker testing and evidence-based biomarker-guided targeted therapy for patients with NSCLC with ROS1 and ALK rearrangements.

With a median follow-up of more than 2.5 years, sintilimab added to chemotherapy improved OS in patients with advanced, nonsquamous NSCLC. The median OS was 24.2 months with sintilimab and 16.8 months with chemotherapy alone. Nearly half of patients in the chemotherapy-only arm crossed over to receive sintilimab after disease progression. When the data were adjusted for the crossover effect, the OS benefit derived from sintilimab was more pronounced.